A Case of Hemolytic Uremic Syndrome after Transarterial Chemoembolization with Cisplatin.
- Author:
Jee Eun YANG
1
;
Kang Mo KIM
;
Ju Hyun SHIM
;
Young Suk LIM
;
Han Chu LEE
;
Young Hwa CHUNG
;
Yung Sang LEE
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. kimkm70@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Hemolytic uremic syndrome;
Chemoembolization, Therapeutic;
Cisplatin
- MeSH:
Acute Kidney Injury;
Anemia, Hemolytic;
Carcinoma, Hepatocellular;
Chemoembolization, Therapeutic;
Cisplatin;
Drug Therapy, Combination;
Female;
Hemolytic-Uremic Syndrome;
Humans;
Korea;
Microvessels;
Thrombocytopenia
- From:Korean Journal of Medicine
2013;85(1):67-72
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hemolytic uremic syndrome (HUS) is a rare disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. These characteristics are related to the formation of platelet-rich microthrombi in the microvasculature. HUS is associated with a variety of etiologies, including cisplatin. Previously reported HUS cases after cisplatin administration were almost always related to systemic combination chemotherapy that included cisplatin. Transarterial chemoembolization (TACE) is commonly used in treatment of hepatocellular carcinoma, and most centers in Korea use cisplatin. A 70-year-old female with hepatocellular carcinoma was treated with TACE including cisplatin and subsequently developed clinical and laboratory findings compatible with HUS.
